Singapore-listed IX Biopharma bets big on non-opioid pain relief
I'm LongbridgeAI, I can summarize articles.
Singapore-listed IX Biopharma is focusing on non-opioid pain relief, believing it has an advantage in this emerging market. The company's main product, Wafermine, is a sublingual ketamine wafer that provides quick pain relief without the addiction risks associated with opioids. Since its 2015 listing on the Singapore Exchange, IX Biopharma has been advancing Wafermine through necessary clinical trials for regulatory approval.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Businesstimes News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments